Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 7/20 | 0.47 |
| ▸ | IDO1 | P14902 | 2/20 | 0.47 |
| ▸ | USP5 | P45974 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL661514 | 0.76 | DGAT1 (0.59) | IDO1USP5ALDH1A1SMN1; SMN2CYP1A2 | |
| SCHEMBL2698138 | 0.75 | ESR2 (0.49) | — | |
| SCHEMBL2698142 | 0.75 | ESR2 (0.49) | — | |
| SCHEMBL3577595 | 0.74 | NPC1 (0.68) | ALDH1A1SMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL663308 | 0.73 | SMN1; SMN2 (0.43) | IDO1USP5ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL663307 | 0.73 | SMN1; SMN2 (0.43) | IDO1USP5ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL5177202 | 0.70 | RAB9A (0.51) | CCR1IDO1USP5SMN1; SMN2 | |
| SCHEMBL3573449 | 0.70 | NPC1 (0.64) | ALDH1A1SMN1; SMN2CYP1A2NFKB1 | |
| SCHEMBL9584535 | 0.70 | CYP1A2 (0.78) | ALDH1A1SMN1; SMN2CYP1A2TSHRNFKB1 | |
| SCHEMBL4975063 | 0.69 | IDO1 (0.48) | CCR1IDO1CYP1A2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2423182-A1 | DIACYLETHYLENEDIAMINE COMPOUND | Astellas Pharma Inc. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | ASTELLAS PHARMA INC. (JP) | 2012-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120046292-A1 | DIACYLETHYLENEDIAMINE COMPOUND | DGAT1, DGAT2, DIMT1 | CCR1 4300/4885IDO1 1181/4885USP5 3672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.